# First FDA approval and US commercial launch, MedinCell enters new era

Euronext: MEDCL • Montpellier, France • 2 May 2023, 8am CEST

**MedinCell will hold a video conference for its shareholders and the financial community on May 2nd, 2023**

**6:30pm CEST in French, to connect: www.medincell.com/fr/investisseurs/#events_**

**7:30pm CEST in English, to connect: www.medincell.com/en/investors/#events_**

**MedinCell and its partner Teva have announced FDA approval of mdc-IRM, the first product based on MedinCell's BEPO® technology[1]**

**The new treatment for schizophrenia will be available in the U.S. in the coming weeks under the brand name UZEDY™**

**MedinCell is entitled to receive royalties on all sales and is eligible for up to $105 million in commercial milestones**

**Two other products based on the same MedinCell's BEPO® technology are currently in Phase 3 and several others are in development**

---

Christophe Douat, CEO of MedinCell declared: *"It is an emotional moment at Medincell. We are at a turning point, an inflection point, and this is just the beginning. FDA approval of UZEDY is an important validation of our technology and know-how. We now have a product reaching market with significant commercial potential in the US. Given UZEDY's differentiating features and positive Phase 3 results, we believe it has the potential to establish a new standard of care for patients with schizophrenia. This major development in the evolution of our company will benefit all the products of our portfolio and increase our visibility. Our team and our partner have done an exceptional job together. This success goes beyond MedinCell, it is also major news for the French biotechnology sector."*

Jaime Arango, Chief Financial Officer of MedinCell said: *"We are reaching the commercial stage with an ideal partner to exploit the full potential of UZEDY. Teva is building a schizophrenia franchise. Its American sales force has recently demonstrated its effectiveness on the same target of prescribers as UZEDY. We are entitled to receive royalties from the first sales and eligible for up to $105 million in commercial milestones in the coming years. In the short term, this approval triggers a $4 million payment from Teva to MedinCell and gives us access to the third tranche of the EIB loan for an amount of €10 million[2]."*

UZEDY is the first product based on MedinCell's proprietary BEPO technology (licensed to Teva under the name SteadyTeq™) to reach market. It is part of MedinCell's growing portfolio that includes other breakthrough treatments, all of which aim at offering innovative therapeutic options that may ensure patient compliance and adherence and provide other benefits that address unmet medical need for existing medications.

***MedinCell portfolio as of May 1st, 2023***



**About MedinCell**

MedinCell is an innovative pharmaceutical company, from development to market, with a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology (licensed to Teva under the name SteadyTeq™) with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance (i.e. compliance with medical prescriptions) and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. MedinCell collaborates with tier one pharmaceuticals companies and foundations to improve Global Health through new therapeutic options. Based in Montpellier, MedinCell currently employs more than 140 people representing over 25 different nationalities.
www.medincell.com

**Contacts**


MedinCell
**David Heuzé**
**Head of Communications**
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
**Louis-Victor Delouvrier / Alban Dufumier**
**Investor Relations**
medincell@newcap.eu
+33 (0)1 44 71 94 94

NewCap
**Nicolas Merigeau**
**Media Relations**
medincell@newcap.eu
+33 (0)1 44 71 94 94




[1] MedinCell and Teva press release, 28 April 2023
[2] MedinCell press releases, 23 November 2022